UDCA Therapy in Primary Biliary Cholangitis–Related Cirrhosis

Indications

• UDCA is recommended only for cholestatic liver diseases, specifically primary biliary cholangitis (PBC), and should be used in patients with PBC‑related cirrhosis because it reduces mortality and hepatic decompensation even when cirrhosis is already compensated. 1
• The British Society of Gastroenterology (BSG) guidelines designate UDCA as the standard first‑line therapy for all PBC patients, including those who have progressed to cirrhosis. 1

Dosing

• Initiate UDCA at 13–15 mg/kg/day, divided into two or three doses; this dose has been shown to be effective in PBC and is higher than the lower dose approved for other cholestatic conditions. 1
• Do not exceed 25 mg/kg/day in patients with cirrhosis or advanced liver disease, as doses of 28–30 mg/kg/day have been linked to adverse outcomes. 2

Response Assessment and Monitoring

• Assess biochemical response at 6 months by measuring alkaline phosphatase, γ‑glutamyl transferase, bilirubin, and transaminases; response criteria guide continuation or adjustment of therapy. 2

Special Populations

• Pregnancy: Continue UDCA before conception, throughout pregnancy, and postpartum in PBC patients with cirrhosis; expert consensus supports its safety despite limited formal trial data. 1
• Portal hypertension in pregnancy: Women with cirrhosis and portal hypertension should undergo elective endoscopy in the second trimester because pregnancy can increase portal pressure. 1

Contraindications

• UDCA is contraindicated in patients with gallstone pancreatitis. 1

Use in Non‑Cholestatic Cirrhosis

• UDCA should not be used for cirrhosis arising from non‑cholestatic causes (e.g., alcohol‑related liver disease, viral hepatitis, NASH) because there is no evidence of benefit and the drug’s anticholestatic mechanism is specific to cholestatic disorders. 2

All facts are derived from cited guideline or evidence sources; where multiple citations existed, the non‑Praxis source was preferred.